Literature DB >> 9205950

Modulation of human cardiac function through 4 beta-adrenoceptor populations.

A J Kaumann1, P Molenaar.   

Abstract

In human heart there is now evidence for the involvement of four beta-adrenoceptor populations, three identical to the recombinant beta 1-, beta 2- and beta 3-adrenoceptors, and a fourth as yet uncloned putative beta-adrenoceptor population, which we designate provisionally as the cardiac putative beta 4-adrenoceptor. This review described novel features of beta-adrenoceptors as modulators of cardiac systolic and diastolic function. We also discuss evidence for modulation by unoccupied beta 1- and beta 2-adrenoceptors. Human cardiac and recombinant beta 1- and beta 2-adrenoceptors are both mainly coupled to adenylyl cyclase through Gs protein, the latter more tightly than the former. Activation of both human beta 1- and beta 2-adrenoceptors not only increases cardiac force during systole but also hastens relaxation through cyclic AMP-dependent phosphorylation of phospholamban and troponin 1, thereby facilitating diastolic function. Furthermore, both beta 1 and beta 2-adrenoceptors can mediate experimental arrhythmias in human cardiac preparations elicited by noradrenaline and adrenaline. Human ventricular beta 3-adrenoceptors appear to be coupled to a pertussis toxin-sensitive protein (Gi?). beta 3-Adrenoceptor-selective agonists shorten the action potential and cause cardiodepression, suggesting direct coupling of a Gi protein to a K+ channel. In a variety of species, including man, cardiac putative beta 4-adrenoceptors mediate cardiostimulant effects of non-conventional partial agonists, i.e. high affinity beta 1- and beta 2-adrenoceptor blockers that cause agonist effects at concentrations considerably higher than those that block these receptors. Putative beta 4-adrenoceptors appear to be coupled positively to a cyclic AMP-dependent cascade and can undergo some desensitisation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9205950     DOI: 10.1007/pl00004999

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  35 in total

1.  Desensitization and resensitization of beta 1- and putative beta 4-adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure.

Authors:  A R Kompa; R J Summers
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

2.  Putative beta 4-adrenoceptors in rat ventricle mediate increases in contractile force and cell Ca2+: comparison with atrial receptors and relationship to (-)-[3H]-CGP 12177 binding.

Authors:  D Sarsero; P Molenaar; A J Kaumann; N S Freestone
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 3.  Cardiac receptor physiology and its application to clinical imaging: present and future.

Authors:  H Tseng; J M Link; J R Stratton; J H Caldwell
Journal:  J Nucl Cardiol       Date:  2001 May-Jun       Impact factor: 5.952

Review 4.  Beta-adrenoceptor polymorphisms.

Authors:  K Leineweber; R Büscher; H Bruck; O-E Brodde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-28       Impact factor: 3.000

5.  Human atrial β(1L)-adrenoceptor but not β₃-adrenoceptor activation increases force and Ca(2+) current at physiological temperature.

Authors:  Torsten Christ; Peter Molenaar; Paul M Klenowski; Ursula Ravens; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

6.  Positive inotropic and lusitropic effects mediated via the low-affinity state of beta1-adrenoceptors in pithed rats.

Authors:  Agnieszka Zakrzeska; Eberhard Schlicker; Grzegorz Kwolek; Hanna Kozłowska; Barbara Malinowska
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

7.  Murine ventricular L-type Ca(2+) current is enhanced by zinterol via beta(1)-adrenoceptors, and is reduced in TG4 mice overexpressing the human beta(2)-adrenoceptor.

Authors:  J F Heubach; E M Graf; P Molenaar; A Jäger; F Schröder; S Herzig; S E Harding; U Ravens
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

8.  Cardiac implications for the use of beta2-adrenoceptor agonists for the management of muscle wasting.

Authors:  Peter Molenaar; Lu Chen; William A Parsonage
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

Review 9.  Cardiac β3 -adrenoceptors-A role in human pathophysiology?

Authors:  Ebru Arioglu-Inan; Gizem Kayki-Mutlu; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-22       Impact factor: 8.739

Review 10.  Sympathetic nervous system activity and ventricular tachyarrhythmias: recent advances.

Authors:  Kelley P Anderson
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-01       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.